Replies to post #458 on Merrimack Pharmaceuticals, Inc. (MACK)

[faxedreceipts]

After doing a lot of dd, it's clear management execution has been superb. On track for European approval with Shire and sales ramping up for Onivyde in the USA. You can't ask for a better spec stock especially with FDA approved Onivyde meets an unmet need in pancreatic cancer treatment and has no competition. MACK has full rights in the USA as well.

The stock price is near 52 week lows and so I initiated a long position.